Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
James F. Oliviero
|
| gptkbp:developsDrug |
CK-103
CK-302 cosibelimab olafertinib |
| gptkbp:focusesOn |
immuno-oncology
targeted oncology therapies |
| gptkbp:foundedYear |
2014
|
| gptkbp:headquartersLocation |
gptkb:Waltham,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Checkpoint Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
CK-103
CK-302 cosibelimab olafertinib |
| gptkbp:parentCompany |
gptkb:Fortress_Biotech
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:specializesIn |
monoclonal antibodies
small molecule inhibitors |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
CKPT
|
| gptkbp:therapeuticArea |
gptkb:cancer
solid tumors hematological malignancies |
| gptkbp:tradedOn |
CKPT
|
| gptkbp:website |
https://www.checkpointtx.com/
|
| gptkbp:bfsParent |
gptkb:Fortress_Biotech
|
| gptkbp:bfsLayer |
7
|